Viking Therapeutics heats up competition in obesity with impressive Phase 2 data
Arctic Aurora portfolio company Viking Therapeutics opened nearly 100% up on positive weight loss data from a Phase 2 study
Obesity is one of the largest societal and healthcare burdens globally. It is estimated to affect more than 650 million people, who are at a higher risk of developing more than 200 health complications including diabetes, cardiovascular problems, and fatty liver disease. In the recent years, multiple drugs have been developed to address this global challenge.
Arctic Aurora LifeScience and Arctic Aurora Biotech Select portfolio company Viking Therapeutics is a strong contender in the obesity space. Today, they announced competitive Phase 2 results of their drug candidate, VK2735. Obese patients in the trial achieved a placebo-adjusted weight loss of up to 13.1% after just 13 weeks. Importantly, weight loss did not plateau at 13 weeks and the treatment was effective in most patients with 88% of them achieving a ≥10% weight loss at the end of the trial. The side effects of the drug were comparable to other similar treatments.
VK2735 is a dual activator of the glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors. Effect on these receptors is associated with reduced body weight and appetite, and higher sensitivity to insulin. Among the drugs that are already approved, semaglutide (brand name Ozempic/Wegovy, marketed by Novo Nordisk) acts on GLP-1 while tirzepatide (Mounjaro/Zepbound by Eli Lilly) is a dual activator of the GLP-1/GIP receptors similarly to VK2735. According to consensus, the size of the obesity market will reach USD 100-150 billion and the peak sales of semaglutide and tirzepatide are expected to be USD 40 billion and USD 45 billion, respectively.
Latest news
Arctic Asset Management - Arctic Midt i Måneden - Sterke rapporter og nye markedsmuligheter
Rapporteringssesongen i Norden har gitt flere positive overraskelser, med solide resultater på tvers av både industri, bank og råvarerelaterte selskaper. Samtidig vurderer markedet utsiktene for renter, inflasjon og videre vekst i en verden preget av økt usikkerhet.
I denne episoden av Arctic Midt i Måneden møter Albert Collett forvalterne Vegard Kjølhamar og Alexander Larstedt Lager til en samtale om de viktigste trendene fra rapporteringssesongen, utviklingen i rente- og kredittmarkedene og hvordan fondene er posisjonert for månedene fremover.
Arctic Asset Management - Markedskommentar april 2026
April ble en måned der markedene forsøkte å prise konsekvensene av det kraftige råvare- og energisjokket fra Midtøsten. Den kraftig reduserte skipstrafikken gjennom Hormuz-stredet skapte fortsatt betydelig usikkerhet rundt olje, gass og flere andre råvarer. Markedet priset fortsatt inn en gradvis normalisering, men risikoen for en mer langvarig forstyrrelse økte etter hvert som skipstrafikken forble kraftig redusert og buffere i form av lagre og allerede lastede skip gradvis ble brukt opp. Utfallet fremstår derfor fortsatt binært: enten en gradvis gjenåpning og lavere energipriser, eller en mer akutt fase dersom blokaden vedvarer inn i sommermånedene.
Arctic Asset Management - Revolution Medicines announced unprecedented Phase 3 results in pancreatic cancer
Arctic Aurora LifeScience holding, Revolution Medicines announced outstanding overall survival benefit in metastatic pancreatic cancer, one of the most lethal tumors.
Arctic Asset Management - Markedskommentar mars 2026
Markedene i mars ble påvirket av krigen i Iran som har spredt seg til store deler av Midtøsten og skapt betydelige globale ringvirkninger. Etter at USA og Israel angrep Iran på den siste dagen i februar, har regionen vært preget av krigshandlinger, med påfølgende avbrudd i råvareproduksjon og forsyningskjeder som har gitt økt markedsvolatilitet.
Arctic Asset Management - No slowing down of Biotech M&A: Soleno to be acquired by Neurocrine
On April 6, Arctic Aurora LifeScience holdings Soleno Therapeutics and Neurocrine Biosciences announced an agreement in which the mid-cap commercial biotech Neurocrine acquires Soleno for USD 2.9 billion or USD 53 per share - a 34% premium over the last closing price.
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.